The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial.
Over the past 2 decades, the number of cancer deaths per 100,000 blacks has declined approximately 30% in the United States, but black people are still disproportionately dying of cancer.
Researchers have identified 2 inherited pathogenic genetic variants in patients with pediatric neuroblastoma, according to results from a study presented at the 2021 virtual American Association for Cancer Research annual meeting.
